Hybio Pharmaceutical Co., Ltd.

¥24.14As of Sun 8 Nov 2026, 12:00 UTC
SZSE:300199Healthcare
Country China
PE (Fwd) •••
TSR 10Y CAGR 1.48%
Div yield —
ROE 45.60%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.92
PE TTM 54.88
TSR TTM 14.62%
Mkt cap ¥21.32B
ROIC 15.59%
SE Grade™
Value
Quality
Moat
Consensus
Reference
¥27
10.93%
(40.78%)
Hold 5|5|2|11|4
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.43
0.45
0.44
0.48
18.35%
16.33%
15.09%
17.90%
Revenue¥B
1.248
1.211
1.235
1.211
(1.33%)
(2.30%)
(0.41%)
(2.33%)
Peers (US$3.196B)
Cap (US$)
PE
3.178B
23.24x
Capital
TTM
5Y
10Y
Leveragex
2.609
(0.270)
(0.259)
EBIT/Intx
0.614
0.117
0.116
Own earn%
(32.83)
108.47
113.79
Sh yield%
26.65
41.31
39.73
Owners
Insiders/Inst%
12.81
87.98
Short interest%
3.18
SBC / revenue%
0.98
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
7
Op margin range%
24–28
$1 testx
−0.1
Incr. ROIC%
7